Many new therapies, some of them in phase I or II clinical trials (May 07)
are targeting the HGF/c-Met
pathway :
- anti HGF monoclonal antibodies
- truncated variants of c-Met that act as decoys for HGF
- anti-c-Met monoclonals
- protein kinase inhibitors that block c-Met induced pathways (XL 184, ARQ197, XL880, SGX523, MP470,
PF2341066)
Abbreviations : ERK extracellular regulated kinase, Gab1 growth factor receptor bound protein 2 associated binder 1, GRB2 growth factor receptor bound protein 2, HGF hepatocyte growth factor, MAPK mitogen activated protein kinase, Mek MAP-ERK kinase, PI3K phosphoinositide kinase, STAT signal transducer and activator of transcription, Raf rat fibrosarcoma, Ras rat sarcoma
